ViroGates A/S

As of June 30, 2026, ViroGates A/S carries a market capitalization of 101.17M, placing it among publicly traded companies globally. Its enterprise value stands at 87.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ViroGates A/S's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, ViroGates A/S has 9.28M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 10.13, and the price-to-book ratio stands at 6.24.

These figures are as of June 30, 2026. The EV/Sales ratio of 9.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 87.47M versus a market cap of 101.17M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ViroGates A/S maintains a current ratio of 6.90, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 24.27, indicating elevated leverage, while an interest coverage ratio of -18.22 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ViroGates A/S posted a negative return on equity (ROE) of -72.15, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.77, reflecting losses generated across the asset base. The company generates approximately 1.21M in revenue per employee across its workforce of 7.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.07 indicates how many times ViroGates A/S sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ViroGates A/S recorded an income tax benefit of -1.02M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -8.59M and -7.56M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 20, 2026, ViroGates A/S's stock has declined approximately 37.74% over the past 52 weeks. The 50-day moving average sits at 9.79, while the 200-day moving average is 11.25.

Over the twelve months ended June 30, 2026, ViroGates A/S generated 9.36M in revenue and converted that into -7.56M in net income, yielding earnings per share of -0.87. EBITDA reached -8.54M, while operating income came in at -8.54M.

As of June 30, 2026, ViroGates A/S holds 17.64M in cash and equivalents against 3.93M in total debt, resulting in a net debt position of -13.70M. Total book value stands at 16.20M, with working capital of 18.72M providing operational flexibility.

ViroGates A/S produced -12.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -12.14M - equivalent to -1.40 per share.

Over the twelve months ended June 30, 2026, ViroGates A/S posted a gross margin of 78.16, reflecting its pricing power and cost economics. The operating margin of -91.26 and net profit margin of -80.81 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -12.81: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.68, meaning ViroGates A/S raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ViroGates A/S's most recent stock split took place on November 28, 2023 with a 64:83 split ratio.

As of June 30, 2026, ViroGates A/S has an Altman Z-Score of 10.94, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.